Mogul Games Group Ltd

MGG

Mogul Games Group Ltd. engages in the business of design and development of its online media platform. The company is headquartered in Melbourne, Victoria and currently employs 3 full-time employees. The company went IPO on 2011-10-19. The principal activities of the Company consists of gaming, esports media and software business. The firm owns and operates mogul.gg tournament platform, which is a an online esports tournament and matchmaking platform with automation for esports titles. The firm operates in two segments: eSports and Unallocated. The eSports segment consists of equity investments and intangible assets and all expenses related to the eSports business. The Unallocated segment consists of corporate, including treasury, corporate, and regulatory expenses arising from operating an entity. The firm's subsidiaries include eSports Nominees Pty Ltd, SEA Esports Pte Ltd, and GameGeek Pte Ltd.

Trigg Minerals Limited

TMG

Trigg Minerals Ltd. engages in the exploration and development of brine-hosted fertiliser minerals that are critical for the production of high-nutrient food sources. The firm owns 100% of the Drummond epithermal gold project, which incorporates five granted exploration permits covering approximately 540 square kilometers (km2) in the Drummond Basin, over 150 kilometers (km) south of Townsville, Queensland. The company also has a 90% interest in four new license areas comprising over 431km2 in northern Queensland. Clarke Reward (EPM27834) covers an area of 96km2 in Queensland’s Drummond Basin, and is 17km west of the Mt Coolon gold mine. Mt Carmel (EPM27991) covers over 118km2 of a highly anomalous magnetic feature in a structural position within Queensland’s Drummond Basin. West Ravenswood (EPM27752) covers over 117km2 southeast of Charters Towers in northern Queensland. The company also owns the Lake Throssell sulfate of potash (SOP) project in Western Australia.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.